Michael S Vincent
Overview
Explore the profile of Michael S Vincent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peeva E, Guttman-Yassky E, Yamaguchi Y, Berman B, Oemar B, Ramakrishna J, et al.
Drug Discov Today
. 2025 Feb;
30(3):104317.
PMID: 39986647
Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and...
2.
Fiorentino D, Mangold A, Werth V, Christopher-Stine L, Femia A, Chu M, et al.
Lancet
. 2025 Jan;
405(10473):137-146.
PMID: 39798982
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess...
3.
Danto S, Tsamandouras N, Reddy P, Gilbert S, Mancuso J, Page K, et al.
Allergy Asthma Clin Immunol
. 2024 Aug;
20(1):46.
PMID: 39215351
PF-06817024 is a humanized antibody against interleukin-33 that has the potential to inhibit type 2 inflammation. An exploratory analysis of the pharmacodynamics and clinical effects of single and repeat doses...
4.
Cohen S, Beebe J, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M, et al.
Arthritis Res Ther
. 2024 Jun;
26(1):117.
PMID: 38845046
Background: The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5...
5.
Peeva E, Banerjee A, Banfield C, Soma K, Christensen J, Menon S, et al.
Drug Discov Today
. 2024 Mar;
29(5):103948.
PMID: 38460567
Master protocol designs, such as umbrella and basket studies, allow multiple compounds or multiple target populations to be evaluated simultaneously within a single protocol, and have been widely adopted in...
6.
Tehlirian C, Peeva E, Kieras E, Scaramozza M, Roberts E, Singh R, et al.
Lancet Rheumatol
. 2024 Jan;
3(3):e204-e213.
PMID: 38279383
Background: Blockade of tyrosine kinase 2 (TYK2) signalling has previously shown therapeutic potential in the treatment of psoriasis. The primary objective of this study was to assess the safety and...
7.
Eichenfield L, Tarabar S, Forman S, Garcia-Bello A, Feng G, Fetterly G, et al.
JAMA Dermatol
. 2023 Dec;
160(2):156-163.
PMID: 38117526
Importance: Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions. Objective: To assess the efficacy and safety...
8.
Danto S, Tsamandouras N, Reddy P, Gilbert S, Mancuso J, Page K, et al.
J Clin Pharmacol
. 2023 Sep;
64(5):529-543.
PMID: 37772436
PF-06817024 is a high affinity, humanized antibody that binds interleukin-33, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized,...
9.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, et al.
Arthritis Rheumatol
. 2023 May;
75(8):1370-1380.
PMID: 37194394
Objective: Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately-to-severely active psoriatic...
10.
Li W, Crouse K, Alley J, Frisbie R, Fish S, Andreyeva T, et al.
J Pharmacol Exp Ther
. 2023 May;
386(1):80-92.
PMID: 37142443
Blocking chemokine receptor C-C chemoattractant cytokine (chemokine) receptor (CCR) 6-dependent T cell migration has therapeutic promise in inflammatory diseases. PF-07054894 is a novel CCR6 antagonist that blocked only CCR6, CCR7,...